Literature DB >> 12804460

Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients.

M D van de Wetering1, J B M van Woensel.   

Abstract

BACKGROUND: Long-term tunnelled central venous catheters (TCVC) are increasingly used in oncology patients. Despite guidelines on insertion, maintenance and use, infections remain an important complication. Most infections are caused by Gram-positive bacteria. Therefore antimicrobial prevention strategies aimed at these micro-organisms could potentially decrease the majority of the TCVC infections.
OBJECTIVES: To determine the efficacy of administering antibiotics prior to insertion of a TCVC with or without vancomycin/heparin flush technique in the first 45 days after insertion of the catheter to prevent Gram-positive catheter-related infections in oncology patients. SEARCH STRATEGY: We searched MEDLINE, EMBASE,and CENTRAL up to July 2001. Reference lists from relevant articles were scanned and conference proceedings were hand searched. The authors of eligible studies were contacted to obtain additional information. SELECTION CRITERIA: We selected randomized controlled trials giving prophylactic antibiotics prior to insertion of the TCVC, and trials using the combination of an antibiotic and heparin to flush the TCVC in oncology patients. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed the studies for inclusion, extracted the data and assessed the quality. MAIN
RESULTS: We included eight trials totalling 527 patients. Four reported on vancomycin/teicoplanin prior to insertion of the TCVC, and four reported on antibiotic flushing combined with heparin. The overall effect of an antibiotic prior to catheter insertion decreases the number of Gram-positive TCVC infections (odds ratio [OR] = 0.55, 95% confidence interval [CI] 0.29 to1.04). Given an expected infection rate of TCVC during the first 45 days of up to 30% this OR implies that the number needed to treat (NNT) will be 10 (95% CI 4 to13), this means vancomycin needs to be given to 10 patients to prevent one TCVC infection. Flushing the TCVC with antibiotics and heparin proved to be beneficial (OR = 0.35, 95% CI 0.16 -to 0.77). For intraluminal colonization the baseline infection-rate is 15% which leads to a NNT of 13 (95% CI 5 to 23). REVIEWER'S
CONCLUSIONS: Both interventions lead to a positive overall effect but should be considered with care due to the small number of studies. Depending on the baseline TCVC infection rate it is justified to administer antibiotics prior to the TCVC insertion or to flush the catheter with a combination of an antibiotic and heparin, if the catheter-related infection rate is high.

Entities:  

Mesh:

Year:  2003        PMID: 12804460     DOI: 10.1002/14651858.CD003295

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  5 in total

1.  Port catheter versus peripherally inserted central catheter for postoperative chemotherapy in early breast cancer: a retrospective analysis of 448 patients.

Authors:  L Lefebvre; E Noyon; D Georgescu; V Proust; C Alexandru; M Leheurteur; J C Thery; L Savary; O Rigal; F Di Fiore; C Veyret; F Clatot
Journal:  Support Care Cancer       Date:  2015-09-05       Impact factor: 3.603

2.  Prophylactic antibiotic guidelines in modern interventional radiology practice.

Authors:  Eunice Moon; Matthew D B S Tam; Raghid N Kikano; Karunakaravel Karuppasamy
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

3.  epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England.

Authors:  H P Loveday; J A Wilson; R J Pratt; M Golsorkhi; A Tingle; A Bak; J Browne; J Prieto; M Wilcox
Journal:  J Hosp Infect       Date:  2014-01       Impact factor: 3.926

4.  Practical approach to catheter-related bloodstream infections in paediatrics.

Authors:  Joan Robinson
Journal:  Paediatr Child Health       Date:  2005-10       Impact factor: 2.253

5.  epic2: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England.

Authors:  R J Pratt; C M Pellowe; J A Wilson; H P Loveday; P J Harper; S R L J Jones; C McDougall; M H Wilcox
Journal:  J Hosp Infect       Date:  2007-02       Impact factor: 3.926

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.